![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16"><rect fill-opacity="0"/></svg>)
FDA approves Alzheimer’s drug that slowed cognitive decline in clinical trial
Summary by Ground News
The Food and Drug Administration on Friday approved an Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness.Hide image
Published 4 days ago · Washington, United States Photography Anadolu Ajansı
News Articles
More Filters
All
Left
Center
Right
![Georgia Public Broadcasting](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="24" height="24"><rect fill-opacity="0"/></svg>){kind=small}
Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval
By Julie Steenhuysen and Deena Beasley (Reuters) -The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of
3 days ago·San Diego, United States
Read Full ArticleInsights![Medscape](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="48" height="48"><rect fill-opacity="0"/></svg>)
Medscape broke the news in United States 5 days ago on Friday, January 6, 2023.
This report's coverage is mostly Center.
Share it to spread the word.
Share it to spread the word.
Medscape broke the news in United States 5 days ago on Friday, January 6, 2023.Similar News Topics
InsightsMedscape broke the news in United States 5 days ago on Friday, January 6, 2023.
This report's coverage is mostly Center.
Share it to spread the word.
Share it to spread the word.
Medscape broke the news in United States 5 days ago on Friday, January 6, 2023.Time & Location
![Georgia Public Broadcasting](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="50" height="50"><rect fill-opacity="0"/></svg>)
Bias Distribution
59% of the sources are Center
+40
+106
+19
+1
L 25%
C 59%
R 16%
Untracked bias
+56
See less detail
